|Bid||17.08 x 1200|
|Ask||22.00 x 900|
|Day's Range||18.56 - 19.88|
|52 Week Range||15.60 - 36.35|
|Beta (3Y Monthly)||1.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 13, 2019 - Feb 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.11|
Acorda's (ACOR) lead MS drug Ampyra is hit by generic competition in the United States while its lead Parkinson disease candidate Inbrija's review timeline gets extended by three months.
NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Acorda Therapeutics, Inc. (ACOR) announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the Stifel 2018 Healthcare Conference on Tuesday, November 13 at 2:00pm EST. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA™ (levodopa inhalation powder), an investigational inhaled formulation of levodopa for symptoms of OFF periods for people with Parkinson’s on a carbidopa/levodopa regimen, is under FDA review with a PDUFA date of January 5, 2019.
Acorda's (ACOR) Q3 rides high on earnings and revenue beat amid a strong generic competition for its MS drug Ampyra and the expected launch of its Parkinson's candidate, Inbrija.
Acorda (ACOR) delivered earnings and revenue surprises of 13.33% and 68.52%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Ardsley, New York-based company said it had a loss of 29 cents per share. Earnings, adjusted for one-time gains and costs, were 17 cents per share. The results exceeded Wall Street expectations. The ...
ARDSLEY, N.Y.-- -- AMPYRA ® Q3 2018 net revenue of $138 million; 2018 net revenue guidance increased from $330-$350 million to more than $400 million Cash balance for year-end 2018 revised from more than $300 million to more than $400 million INBRIJA™ PDUFA date January 5, 2019 Acorda Therapeutics, Inc. provided a financial and pipeline update for the third quarter ended September 30, 2018. “Acorda’s ...
Presentations at the European Society of Medical Oncology meeting created some volatility in stocks, while the week also saw earnings releases from big-cap pharma companies. The following catalytic events ...
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Acorda Therapeutics, Inc. will host a conference call and webcast to report its third quarter 2018 update and financial results on Wednesday, October 31 at 8:30 a.m. ET.
Here are a few catalysts that can dictate the directional moves of biotech stocks in the upcoming week: Conferences European Society For Medical Oncology, or ESMO, 2018 Congress – Oct. 19-23, in Munich, ...
In September, the FDA extended Acorda Therapeutics’ (ACOR) PDUFA (Prescription Drug User Fee Act) action date for its NDA (New Drug Application) of Inbrija from October 5 to January 5, 2019. The FDA extended Acorda Therapeutics’ PDUFA action date after the submission of additional information that the FDA requested.
As we step into the final quarter of 2018, biotech stocks have recorded double-digit gains for the year-to-date period. Will the run up continue? Stay tuned to the following events of the upcoming week. ...
In October, of the 17 analysts covering Intercept Pharmaceuticals (ICPT), eight have given the stock “buy” or higher ratings, and eight have given it “hold” ratings. One analyst has given Intercept a “sell.”
On September 21, Mylan (MYL) launched its authorized generic version of Acorda Therapeutics’ (ACOR) Ampyra (dalfampridine), which is used for improvement in walking for adults who have multiple sclerosis. Mylan’s dalfampridine extended-release tablets are available in 10 mg tablets, similar to Acorda’s Ampyra. On September 21, MYL stock rose ~2.2% before closing up ~0.67% over the previous day’s closing price.
Acorda Therapeutics, Inc. (ACOR) will present a new post-hoc efficacy analysis from SPAN-PD, the pivotal Phase 3 trial of INBRIJA, at the upcoming International Congress of Parkinson’s Disease and Movement Disorders® taking place October 5-9, 2018 in Hong Kong. INBRIJA is an investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen. The INBRIJA poster, Efficacy of CVT-301 (levodopa inhalation powder) for treatment of OFF periods in Parkinson’s disease (Abstract #369), will be presented on Saturday, October 6, 2018, as part of the Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment poster session from 1:45 PM to 3:15 PM. Posters will be available for viewing from 9:00 AM to 5:00 PM.
The FDA defers decision by three months regarding the NDA of Acorda's (ACOR) Parkinson's disease candidate Inbrija for the treatment of OFF periods.